Li 2012.

Methods	Study design: Randomised clinical trial Study duration: July 2006 to September 2010. Duration of follow‐up: 2 years Setting: Hospital
Participants	Inclusion criteria: diagnosed as HCC by biopsy and images Age (mean, range): TACE + ultrasound ablation: 55 years, 31‐77 years; TACE: 53 years, 28‐69 years Male (n/total): TACE + ultrasound ablation: 24/33; TACE: 23/33 TNM stage (patients): TNM Ⅱ: TACE + ultrasound ablation: 10; TACE: 9 TNM III: TACE + ultrasound ablation: 15; TACE: 16 TNM IV: TACE + ultrasound ablation: 8; TACE: 7
Interventions	TACE + ultrasound ablation group (n = 33): TACE: TACE was performed 1‐2 times. The average sessions of TACE treatment was 1.5 sessions. Ultrasound ablation: The interval between TACE and ultrasound ablation was 2‐3 weeks. Frequency of 0.8 or 1.6 MHz, output power of 250‐400 W, focal length of 135 mm and treatment duration of 436‐8955 s TACE group (n = 33): Chemotherapeutic drugs: pingyangmycin 8 mg. TACE was performed 1‐3 times, with an interval of 3‐4 weeks. The average sessions of TACE treatment was 2.3 sessions.
Outcomes	Serum level of AFP Liver function Survival rate: at 6 months and 1 year after treatment
Notes	Country of study: China Source of funding: National important basic project (2011CB707905) There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.